高脂血症不良反应在多靶点抗肿瘤药物疗效预测中的作用研究进展

Research progress on the role of hyperlipidemia in efficacy prediction of multitargeted antitumor drugs

多靶点抗肿瘤药物在肿瘤治疗领域已取得显著疗效,高脂血症作为常见的不良反应正在被广泛关注。本文选取5种临床应用较多的同类药物,重点关注其高脂血症的发病现状,并对可能诱发高脂血症的机制进行探讨,旨在探索高脂血症与该类药物疗效之间的关联,为进一步阐明相关机制奠定基础,从而有助于筛选合适的目标治疗患者,制订合理的治疗方案,提高患者的生存获益。

Multitargeted tyrosine kinase inhibitors have shown significant therapeutic effects in antitumor therapy. As one of the most common side effects, hyperlipidemia has drawn increasing attentions. Five similar drugs were selected in this review in order to investigate the relationship between hyperlipidemia and therapeutic outcomes of multitargeted tyrosine kinase inhibitors and further illustrate the underlying mechanisms. The reported occurrences of hyperlipidemia in patients treated with them were summarized and possible mechanisms of treatment-induced hyperlipidemia were discussed, which would benefit for searching optimal targeted patients and designing rational therapeutic schedules to improve the survival benefits of patients with carcinomas.